Plasma homocysteine status in patients with ankylosing spondylitis

Clinical Rheumatology

Volumn 26, Issue 5, 2007, Pages 739-742

  Wei, James Cheng Chung ^a   Jan, Ming Shiou ^a   Yu, Chen Tung ^d   Huang, Yi Chia ^a   Yang, Chi Chiang ^a   Tsou, Hsi Kai ^b   Lee, Hong Shan ^a   Chou, Chang Tei ^c   Tsay, Gregory ^a   Chou, Ming Chih ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Ankylosing spondylitis; Folic acid; Homocysteine; Vitamin

Indexed keywords

CYANOCOBALAMIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOXINE; SALAZOSULFAPYRIDINE;

AMINO ACID BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC KIT; DIET RESTRICTION; DISEASE ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RATING SCALE; VITAMIN SUPPLEMENTATION;

ANTIRHEUMATIC AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; HOMOCYSTEINE; HUMANS; METHOTREXATE; SPONDYLITIS, ANKYLOSING; SULFASALAZINE;

EID: 34147106573     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0396-x     Document Type: Article

References (11)

1. Montalescot G, Ankri A, Chadefaux-Vekemans B et al (1997) Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol 60:295-300
2. Boers GH, Smals AG, Trijbels FJ et al (1985) Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313:709-815
3. Taylor LM Jr, DeFrang RD, Harris EJ Jr, Porter JM (1991) The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 13:128-136
4. Brattstrom LE, Hardebp E, Hultberg BL (1984) Moderate homocysteinemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 15:1012-1016
5. Hornung N, Ellingsen T, Stengaard-Pedersen K, Poulsen JH (2004) Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol 31(12):2374-2381
6. Krogh Jensen M, Ekelund S, Svendsen L (1996) Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest 56(5):421-429
7. Chilvers MM, Wordsworth P, Stubbs A, Gao XM (1998) TCR usage by homocysteine-specific human CTL. J Immunol 160(8):3737-3742
8. Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: Relevance of systemic inflammation. Clin Sci (Lond) 109(2):171-176
9. Gao XM, Wordsworth P, McMichael AJ, Kyaw MM, Seifert M, Rees D et al (1996) Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol 26(7):1443-1450
10. D'Angelo A, Selhub J (1997) Homocysteine and thrombotic disease. Blood 90:1-11
11. Clarke R, Daly L, Robinson K et al (1991) Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324:1149-1155